Acelyrin, Inc. (SLRN)
May 21, 2025 - SLRN was delisted (reason: merged into ALMS)
2.250
-0.020 (-0.88%)
Inactive · Last trade price
on May 21, 2025
Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED).
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Acelyrin, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 5, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Mina Kim |
Contact Details
Address: 4149 Liberty Canyon Road Agoura Hills, California 91301 United States | |
| Phone | 805 456 4393 |
| Website | acelyrin.com |
Stock Details
| Ticker Symbol | SLRN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001962918 |
| CUSIP Number | 00445A100 |
| ISIN Number | US00445A1007 |
| Employer ID | 85-2406735 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mina Kim J.D. | Chief Executive Officer and Director |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer |
| Tyler Marciniak | Vice President of Investor Relations, Communications and Corporate Operations |
| K. Amar Murugan J.D. | Chief Legal Officer |
| Kelly Chow | Chief People Officer |
| Kenneth A. Lock | Chief Commercial Officer |
| Patricia A. Turney | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2025 | 25-NSE | Filing |
| May 21, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 425 | Filing |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 1, 2025 | 425 | Filing |
| Apr 30, 2025 | SCHEDULE 13D | Filing |
| Apr 29, 2025 | SCHEDULE 13D/A | Filing |
| Apr 29, 2025 | 425 | Filing |